메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

Servier acquires potential treatment for Fragile X syndrome, the most common genetic cause of autism spectrum disorder

Servier acquires KER-0193, a potential treatment for Fragile X syndrome, developed by Kaerus Bioscience, a Medicxi company KER-0193, a novel, orally bioavailable small molecule, was granted Orphan Drug Designation and Rare Pediatric Drug Designation by U.S. FDA Acquisition strengthens Servier's neurology pipeline in line with its 2030 strategy SURESNES, France, Sept. 8, 2025 -- Servier, an independent international pharmaceutical group governed by a foundation, today announced that it has entered into a definitive agreement with Kaerus Bioscience for the acquisition
- 김갑성 기자
- 2025-09-08 15:49
Gushengtang's H1 2025 Net Profit Climbs 41.6% Driven by Digital Health Adoption and International Expansion

GUANGZHOU, China, Sept. 8, 2025 -- On August 29, Gushengtang (HKG:2273) announced its interim results for 2025, reporting strong operational and financial performance. The company posted revenue of RMB 1.49 billion, representing a 9.5% year-on-year increase. Net profit grew 41.6% year-on-year to RMB 150 million. The expansion in net profit significantly outpaced top-line growth, reflecting improved profitability and greater operating leverage. The company also delivered robust cash flow. Operating cash flow reached RMB 300 million, up 111% from the prior year, while free cash flow tota
- 김갑성 기자
- 2025-09-08 15:35
Siriraj × MIT Hacking Medicine 2025 Now Open for Applications Across Southeast Asia: A Call for Innovation to Tackle Greatest Healthcare Challenges

BANGKOK, Sept. 8, 2025 -- Siriraj Hospital and MIT Hacking Medicine have joined forces once again to host the second edition of their medical innovation hackathon, Siriraj × MIT Hacking Medicine 2025, taking place from October 31 to November 2, 2025. Applications are now open for participants across Southeast Asia. The event aims to bring together multidisciplinary professionals to develop innovative solutions in medical treatment and healthcare services, all within an ecosystem of hospitals, faculties of engineering and accountancy, the private sector, investors, and incubation program
- 김갑성 기자
- 2025-09-08 14:39
Merz Aesthetics® Tops Best Workplaces in Asia™ 2025 List by Great Place To Work®

SINGAPORE, Sept. 8, 2025 -- Merz Aesthetics, the world's largest dedicated medical aesthetics business has officially been recognized as No.1 under Best Workplace in Asia 2025 in the Small & Medium Business category by Great Place To Work, celebrating its commitment to a truly inclusive, people-first culture. With a proud 117-year heritage as a family-owned business, Merz Aesthetics has always taken the long view of success - investing in people, advancing innovation, and nurturing a culture of respect, integrity, and trust. This recognition underscores the company'
- 김갑성 기자
- 2025-09-08 12:50
Sirnaomics Announces Strategic Equity Investment by Bloomage Biotech to Jointly Advance Next-Generation Life Science Pipelines

HONG KONG, Sept. 7, 2025 -- Sirnaomics Ltd. (the "Company", together with its subsidiaries, the "Group" or "Sirnaomics"; Stock Code: 2257), a leading biopharmaceutical company in discovery and development of advanced RNAi therapeutics, today announced that it has entered into a strategic investment agreement with Bloomage Biotech (stock code: 688363.SH) through its wholly-owned subsidiary, Bloomage Biotechnology (Hong Kong) Limited. Under the terms of the agreement, Bloomage Biotech has subscribed for shares in Sirnaomics' strategic placement at HKD 12 per
- 김갑성 기자
- 2025-09-08 12:15
Wel-Bloom and New-In to Exhibit at Vitafoods Asia 2025, Advancing Sustainable Innovation in Nutrition

NEW TAIPEI CITY, Sept. 8, 2025 -- As a leader of jelly supplements, Wel-Bloom Biotech will join its affiliated company New-In in exhibiting at Vitafoods Asia 2025, held in Bangkok, Thailand from September 17 to 19, 2025. The showcase will feature a variety of technologies and Taiwan-sourced ingredient applications, presenting an upgraded one-stop CDMO service that reflects the group's commitment to both nutritional innovation and sustainable manufacturing. Having developed health supplements for brand partners in over 60 countries worldwide, Wel-Bloom is recognized for its high level o
- 김갑성 기자
- 2025-09-08 10:30
Epigenic Therapeutics Announces Completion of $60 Million Series B Financing to Accelerate Clinical Development of Epigenetic Medicines

SHANGHAI, Sept. 8, 2025 -- Epigenic Therapeutics ("Epigenic"), a clinical-stage innovative drug development company, today announced the completion of a $60 million Series B round of financing led by Lapam Capital, with continued participation from existing investors Qiming Venture Partners and OrbiMed, and addition of new investors including IFSC and a renowned investment firm in the industry. This round of funding will primarily support the ongoing clinical development of EPI-003 for chronic hepatitis B functional cure and EPI-001 for hypercholesterolemia treatment. Additionally,
- 김갑성 기자
- 2025-09-08 10:00
Ivonescimab Plus Chemotherapy Demonstrates Consistent Global Benefit: HARMONi Data Update Shows OS HR=0.78, Nominal P=0.0332

[ 메디채널 김갑성 기자 ] The overall survival (OS) hazard ratio (HR) in the HARMONi trial was 0.78, with a nominal p-value of 0.0332 In the North American patients, the OS HR was 0.70 The HARMONi trial has already demonstrated clinically meaningful and statistically significant progression-free survival (PFS) outcomes In the HARMONi trial, clinical endpoint benefits, including OS and PFS, were consistent across Western and Asian patient populations, and these results were also in alignment with the clinical data from the HARMONi-A trial conducted in China HONG KONG, Sept. 7, 2025 -- A
- 김갑성 기자
- 2025-09-07 18:08
New Board, New Strategy: Home Control Taps Global Perspectives to Drive Smart Healthcare Expansion

HONG KONG, Sept. 6, 2025 -- Traditionally in Hong Kong's capital market, Home Control (1747.HK) has often been described as a "hidden gem". The company has maintained a solid financial track record with consistent dividend payouts, yet has rarely been in the market spotlight. Recently, the appointment of several new directors has drawn significant investor attention, propelling the share price to record highs since listing, with a year-to-date gain of more than tenfold. The newly appointed board members bring extensive experience and strong credentials across smart healthcare
- 김갑성 기자
- 2025-09-06 02:07
Huadong Medicine Announces Positive Preliminary Results from a Phase Ⅰ study of HDM2005, a ROR1-Targeting ADC

HANGZHOU, China, Sept. 5, 2025 -- Huadong Medicine Co., Ltd. (hereinafter referred to as "Huadong Medicine") today announced positive preliminary results from a Phase I study of HDM2005, an independently developed Class 1 innovative antibody–drug conjugate (ADC) targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1), in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) or classical Hodgkin lymphoma (cHL). The results showed that HDM2005 demonstrated promising efficacy with a favorable safety and tolerability profile in B-NHL and cHL, which will suppo
- 김갑성 기자
- 2025-09-05 21:38

이전

61 62 63 64 65 66 67 68 69 70

많이 본 기사

최근기사

2025-11-05_WED

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 11월 05일 07시 20분